ACADIA Pharmaceuticals Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Acadia Pharma (ACAD) Tops Q2 EPS by 7c; Raises FY Rev Guidance
July 31, 2019 4:09 PM EDTAcadia Pharma (NASDAQ: ACAD) reported Q2 EPS of ($0.38), $0.07 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $93.2 million versus the consensus estimate of $72.12 million.
Continued execution of our commercial initiatives led to strong quarterly performance for NUPLAZID and a... More
